DESTINY-Breast03 Phase 3 Study Results

Conclusions ● DS-6000a was generally well tolerated, and the recommended dose for expansion (RDE) was declared 8.0 mg/kg DS-6000a demonstrated early clinical signals (RECIST and CA-125 responses) in heavily pretreated patients with advanced platinum- resistant OVC and RCC Expansion cohorts (part B) opened at 8.0 mg/kg are enrolling patients with OVC and RCC ASCO 2022 #3002 Oral Daiichi-Sankyo 108

View entire presentation